Information updates

Updated ASCIA Eczema Resources

With the recent listing of Rinvoq® on the PBS, the following ASCIA resources have been updated to include Dupixent® (dupilumab) and Rinvoq® (upadacitinib) treatments for severe eczema:

 

Both plans are also available at https://www.allergy.org.au/hp/ascia-plans-action-and-treatment#r4a

The FAQ has been updated with the following information under ‘Q 9: How should eczema flares and severe eczema be treated?.’

If prescribed, use a recently listed treatment for severe eczema. There are now two treatments for severe eczema that are listed on the Pharmaceutical Benefits Scheme (PBS) in Australia for people aged 12 years or older with severe eczema which has not responded to other prescribed topical treatments:

  • Dupixent® (dupilumab) is an immune modulating treatment given by injection that is self-administered. Dupilumab works by modifying the body’s immune response to prevent inflammation that plays a central role in eczema, but it is not an immunosuppressant.
  • Rinvoq® (upadacitinib) is a Janus Kinase 1 (JAK1) inhibitor, that is taken as an oral tablet. JAK enzymes create signals in the body's immune system that result in inflammation, so JAK inhibitors work by blocking these signals. This reduces inflammation and the production of immune cells within the body.

It is important to ask your clinical immunology/allergy specialist or dermatologist to see if you are eligible for one of these treatments for severe eczema, which target different parts of the immune system.

 

This news item was issued on 23 March 2022 by Jill Smith, CEO of the Australasian Society of Clinical Immunology and Allergy (ASCIA). ASCIA is the peak professional body for clinical immunology and allergy in Australia and New Zealand.  

Mod ASCIA Member
Donate to AIFA
go to NAS website
ASCIA Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:

About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Accreditiation

healthdirect

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.